
WHAT IS CLAIMED IS:

1. A solid dispersion comprising a compound of Formula I



I

where:

R^0 is chloro;

R^1 and R^2 are H;

R^3 and R^4 are methyl;

A^1 is N and A^2 is CH;

R^5 is nitro;

X –NH–;

Y is $–(CH_2)_n–$ where n is 1; and

R^6 is selected from the group consisting of tetrahydropyranyl and 4-hydrox-4-methyl cyclohexyl;

or a pharmaceutically acceptable salt thereof; wherein the compound of Formula I or the pharmaceutically acceptable salt thereof is dispersed in a solid matrix that comprises (a) at least one pharmaceutically acceptable water-soluble polymeric carrier and (b) at least one pharmaceutically acceptable surfactant, and further wherein no more than 5% of the compound of Formula I or pharmaceutically acceptable salt thereof in the solid dispersion is in crystalline form, as observed by X-ray diffraction analysis.

2. The solid disperson of Claim 1, wherein, in the compound of Formula I, R^6 is4-hydroxy-4-methylcyclohexyl.

3. The solid dispersion of Claim 1, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-

yloxy)benzamide or a pharmaceutically acceptable salt thereof.

4. The solid dispersion of Claim 2, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

5. The solid dispersion of Claim 2, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

6. The solid dispersion of Claim 1, wherein the compound Formula I or pharmaceutically acceptable salt thereof is present in a free base-equivalent amount of 5% to 40% by weight.

7. The solid dispersion of Claim 1, wherein the at least one pharmaceutically acceptable water-soluble polymeric carrier is present in an amount of 40% to 85% by weight and the at least one pharmaceutically acceptable surfactant is present in an amount of 5% to 20% by weight.

8. The solid dispersion of Claim 1, wherein the at least one pharmaceutically acceptable water-soluble polymeric carrier is selected from the group consisting of homopolymers and copolymers of N-vinyl lactams, cellulose esters, cellulose ethers, high molecular weight polyalkylene oxides, polyacrylates, polymethacrylates, polyacrylamides, vinyl acetate polymers, graft copolymers of polyethylene glycol, polyvinyl caprolactam and polyvinyl acetate, oligo- and polysaccharides and mixtures thereof.

9. The solid dispersion of Claim 1, wherein the at least one pharmaceutically acceptable water-soluble polymeric carrier is selected from the group consisting of povidones, copovidones, HPMCs, polyethylene glycol/polyvinyl caprolactam/polyvinyl acetate graft copolymers and mixtures thereof.

10. The solid dispersion of Claim 1, wherein the at least one pharmaceutically acceptable surfactant is non-ionic.

11. The solid dispersion of Claim 1, wherein the at least one pharmaceutically acceptable surfactant is selected from the group consisting of polyoxyethylene glycerides, fatty acid monoesters of sorbitan, polysorbates, α-tocopheryl polyethylene glycol succinate (TPGS) and mixtures thereof.


12. The solid dispersion of Claim 1, wherein no more than 2% of the compound of Formula I or pharmaceutically acceptable salt thereof is in crystalline form, as observed by X-ray diffraction analysis.

13. The solid dispersion of Claim 1, wherein no more than 1% of the compound of Formula I or pharmaceutically acceptable salt thereof is in crystalline form, as observed by X-ray diffraction

analysis.

14. A process for preparing a solid dispersion, comprising:

(a) dissolving in a suitable solvent (i) an active pharmaceutical ingredient (API) comprising a compound of Formula I



I

where:

R^0 is chloro;

R^1 and R^2 are H;

R^3 and R^4 are methyl;

A^1 is N and A^2 is CH;

R^5 is nitro;

X is –NH–;

Y is $-(CH_2)_n-$ where n is 1; and

R^6 is selected from the group consisting of tetrahydropyranyl and 4-hydrox-4-methyl cyclohexyl;

or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable water-soluble polymeric carrier and (iii) at least one pharmaceutically acceptable surfactant; and

(b) removing the solvent to provide a solid matrix comprising the at least one polymeric carrier and the at least one surfactant and having the compound of Formula I or a salt thereof dispersed therein, wherein no more than 5% of thecompound of Formula I or pharmaceutically acceptable salt thereof in the solid dispersion is in crystalline form, as observed by X-ray diffraction analysis.

15. The process of Claim 14, wherein the compound of Formula I is in free-base form; and the process further comprises adding a pharmaceutically acceptable acid before removing the solvent.

16. The process of Claim 14, wherein the step of removing the solvent is performed under heat and/or vacuum.

17. The process of Claim 14, wherein the step of removing the solvent is performed by rotary evaporation or by spray-drying.

18. The process of Claim 14, wherein the step of removing the solvent comprises one or more of methanol, ethanol, acetone, tetrahydrofuran and dichloromethane.

19. The process of Claim 14, wherein the solvent comprises a dichloromethane/methanol or THF/water mixture.

20. The process of Claim 14, wherein no more than 2% of the compound of Formula I or a pharmaceutically acceptable salt thereof in the solid matrix is in crystalline form, as observed by X-ray diffraction analysis.

21. The process of Claim 14, wherein no more than 1% of the compound of Formula I or a pharmaceutically acceptable salt thereof in the solid matrix is in crystalline form, as observed by X-ray diffraction analysis.

22. The process of Claim 14, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

23. The process of Claim 14, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3- b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

24. The process of Claim 14, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

25. The process of claim 22, 23 or 24, wherein the pharmaceutically acceptable water-soluble polymeric carrier is a copovidone.

26. The process of Claim 25, wherein the pharmaceutically acceptable surfactant is a polysorbate.

27. An orally deliverable pharmaceutical dosage form comprising the solid dispersion of Claim 1.

28. The orally deliverable pharmaceutical dosage form of claim 27, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

29. The orally deliverable pharmaceutical dosage form of claim 27, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

30. The orally deliverable pharmaceutical dosage form of claim 27, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

31. The orally deliverable pharmaceutical dosage form of claim 27, whereinthe at least one pharmaceutically acceptable polymeric carrier is copovidone and the at least one surfactant is polysorbate.

32. Use of a therapeutically effective amount of the solid dispersion of Claim 1, in the manufacture of a medicament for treating a neoplastic, immune or autoimmune disease.

33. The use of Claim 32, wherein the disease is a neoplastic disease.

34. The use of Claim 33, wherein the neoplastic disease is selected from the group consisting of cancer, mesothelioma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal and/or duodenal) cancer, chronic lymphocytic leukemia, acute lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid

gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular (hepatic and/or biliary duct) cancer, primary or secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, non-small-cell lung cancer, prostate cancer, small-cell lung cancer, cancer of the kidney and/or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non-Hodgkin's lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblastoma and combinations thereof.

35. The use of Claim 33, wherein the neoplastic disease is a lymphoid malignancy.

36. The use of Claim 35, wherein the lymphoid malignancy is non-Hodgkin's lymphoma.

37. The use of Claim 33, wherein the neoplastic disease is chronic lymphocytic leukemia or acute lymphocytic leukemia.

38. The use of Claim 32, wherein the disease is an immune or autoimmune disease.

39. The use of Claim 32, wherein the solid dispersion is for administering in a

parent-compound-equivalent dose of 50 to 500 mg per day of the compound of Formula I or pharmaceutically acceptable salt thereof at an average treatment interval of 3 hours to 7 days.

40. The use of Claim 32, wherein the solid dispersion is administered once daily in a parent-compound-equivalent dose of 50 to 500 mg per day of the compound of Formula I or pharmaceutically acceptable salt thereof.


41. The use of Claim 32, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

42. The use of claim 32, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

43. The use of Claim 32, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

WHAT IS CLAIMED IS:

1. A solid dispersion comprising a compound of Formula I



I

where:

R_0 is chloro;

R_1 and R_2 are H;

R_3 and R_4 are methyl;

A_1 is N and A_2 is CH;

R_5 is nitro;

X is -NH-;

Y is $-(CH_2)_n-$ where n is 1; and

R_6 is selected from the group consisting of tetrahydropyranyl and 4-hydrox-4-methyl cyclohexyl;

or a pharmaceutically acceptable salt thereof; wherein the compound of Formula I or the pharmaceutically acceptable salt thereof is dispersed in a solid matrix that comprises (a) at least one pharmaceutically acceptable water-soluble polymeric carrier selected from the group consisting of homopolymers and copolymers of N-vinyl lactams, cellulose esters, cellulose ethers, high molecular weight polyalkylene oxides, polyacrylates, polymethacrylates, polyacrylamides, vinyl acetate polymers, graft copolymers of polyethylene glycol, polyvinyl caprolactam and polyvinyl acetate, oligo- and polysaccharides, and mixtures thereof, and (b) at least one pharmaceutically acceptable surfactant selected from the group consisting of polyoxyethylene glycerides, fatty acid monoesters of sorbitan, polysorbates, a-tocopheryl polyethylene glycol succinate (TPGS),

and mixtures thereof, and further wherein no more than 5% of the compound of Formula I or pharmaceutically acceptable salt thereof in the solid dispersion is in crystalline form, as observed by X-ray diffraction analysis.

2. The solid dispersion of Claim 1, wherein, in the compound of Formula I, R_6 is 4-hydroxy-4-methylcyclohexyl.

3. The solid dispersion of Claim 1, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

4. The solid dispersion of Claim 2, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

5. The solid dispersion of Claim 2, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

6. The solid dispersion of Claim 1, wherein the compound of Formula I or pharmaceutically acceptable salt thereof is present in a free base-equivalent amount of 5% to 40% by weight.

7. The solid dispersion of Claim 1, wherein the at least one pharmaceutically acceptable water-soluble polymeric carrier is present in an amount of 40% to 85% by weight and the at least one pharmaceutically acceptable surfactant is present in an amount of 5% to 20% by weight.

8. The solid dispersion of Claim 1, wherein the at least one pharmaceutically


acceptable water-soluble polymeric carrier is selected from the group consisting of povidones, copovidones, HPMCs, polyethylene glycol/polyvinyl caprolactam/polyvinyl acetate graft copolymers and mixtures thereof.

9. The solid dispersion of Claim 1, wherein the at least one pharmaceutically acceptable surfactant is non-ionic.

10. The solid dispersion of Claim 1, wherein no more than 2% of the compound of Formula I or pharmaceutically acceptable salt thereof is in crystalline form, as observed by X-ray diffraction analysis.

11. The solid dispersion of Claim 1, wherein no more than 1% of the compound of Formula I or pharmaceutically acceptable salt thereof is in crystalline form, as observed by X-ray diffraction analysis.

12. A process for preparing a solid dispersion, comprising:
(a) dissolving in a suitable solvent (i) an active pharmaceutical ingredient (API) that is a compound of Formula I



I

where:
R_0 is chloro;
R_1 and R_2 are H;
R_3 and R_4 are methyl;
A_1 is N and A_2 is CH;
R_5 is nitro;

X is -NH-;

Y is $-(CH_2)_n-$ where n is 1; and

R_6 is selected from the group consisting of tetrahydropyranyl and 4-hydrox-4-methyl cyclohexyl;

or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable water-soluble polymeric carrier selected from the group consisting of homopolymers and copolymers of N-vinyl lactams, cellulose esters, cellulose ethers, high molecular weight polyalkylene oxides, polyacrylates, polymethacrylates, polyacrylamides, vinyl acetate polymers, graft copolymers of polyethylene glycol, polyvinyl caprolactam and polyvinyl acetate, oligo and polysaccharides, and mixtures thereof, and (iii) at least one pharmaceutically acceptable surfactant selected from the group consisting of polyoxyethylene glycerides, fatty acid monoesters of sorbitan, polysorbates, a-tocopheryl polyethylene glycol succinate (TPGS), and mixtures thereof; and

(b) removing the solvent to provide a solid matrix comprising the at least one pharmaceutically acceptable water-soluble polymeric carrier and the at least one pharmaceutically acceptable surfactant and having the compound of Formula I or a salt thereof dispersed, wherein no more than 5% of the compound of Formula I or pharmaceutically acceptable salt thereof in the solid dispersion is in crystalline form, as observed by X-ray diffraction analysis.

13. The process of Claim 12, wherein the compound of Formula I is in free-base form; and the process further comprises adding a pharmaceutically acceptable acid before removing the solvent.

14. The process of Claim 12, wherein the step of removing the solvent is performed under heat and/or vacuum.

15. The process of Claim 12, wherein the step of removing the solvent is performed by rotary evaporation or by spray-drying.

16. The process of Claim 12, wherein the solvent comprises one or more of methanol, ethanol, acetone, tetrahydrofuran and dichloromethane.

17. The process of Claim 12, wherein the solvent comprises a

dichloromethane/methanol or THF/water mixture.

18. The process of Claim 12, wherein no more than 2% of the compound of Formula I or pharmaceutically acceptable salt thereof in the solid matrix is in crystalline form, as observed by X-ray diffraction analysis.

19. The process of Claim 12, wherein no more than 1% of the compound of Formula I or pharmaceutically acceptable salt thereof in the solid matrix is in crystalline form, as observed by X-ray diffraction analysis.

20. The process of Claim 12, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

21. The process of Claim 12, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

22. The process of Claim 12, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

23. The process of claim 20, 21, or 22, wherein the pharmaceutically acceptable water-soluble polymeric carrier is a copovidone.

24. The process of Claim 23, wherein the pharmaceutically acceptable surfactant is a polysorbate.

25. An orally deliverable pharmaceutical dosage form comprising the solid dispersion of Claim 1.

26. The orally deliverable pharmaceutical dosage form of claim 25, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

27. The orally deliverable pharmaceutical dosage form of claim 25, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

28. The orally deliverable pharmaceutical dosage form of claim 25, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

29. The orally deliverable pharmaceutical dosage form of claim 25, wherein the at least one pharmaceutically acceptable polymeric carrier is copovidone and the at least one surfactant is polysorbate.

30. Use of a therapeutically acceptable amount of the solid dispersion of Claim 1 in the manufacture of a medicament for treating a neoplastic, immune or autoimmune disease.

31. The use of Claim 30, wherein the disease is a neoplastic disease.

32. The use of Claim 31, wherein the neoplastic disease is selected from the group consisting of cancer, mesothelioma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal and/or duodenal) cancer, chronic lymphocytic leukemia, acute lymphocytic leukemia, esophageal

cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular (hepatic and/or biliary duct) cancer, primary or secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphoma; lymphoblastic leukemia, follicular lymphoma, lymphoid malignancy of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, non-small-cell lung cancer, prostate cancer, small-cell lung cancer, cancer of the kidney and/or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasm of the central nervous system, primary central nervous system lymphoma, non-Hodgkin's lymphoma, spinal axis tumor, brain stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblastoma and combinations thereof.

33. The use of Claim 31, wherein the neoplastic disease is a lymphoid malignancy.

34. The use of Claim 33, wherein the lymphoid malignancy is non-Hodgkin's lymphoma.

35. The use of Claim 31, wherein the neoplastic disease is chronic lymphocytic leukemia or acute lymphocytic leukemia.

36. The use of Claim 30, wherein the disease is an immune or autoimmune disease.

37. The use of Claim 30, wherein the solid dispersion is for administering in a parentcompound-equivalent dose of 50 to 500 mg per day of the compound of Formula I or pharmaceutically acceptable salt thereof at an average treatment interval of 3 hours to 7 days.

38. The use of Claim 30, wherein the solid dispersion is administered once daily in a parent-compound-equivalent dose of 50 to 500 mg per day of the compound of Formula I or pharmaceutically acceptable salt thereof.

39. The use of Claim 30, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-

[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

40. The use of claim 30, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

41. The use of Claim 30, wherein the compound of Formula I is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.